2025
Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care
Hamid S, Lee D, Herrin J, Yu J, Pollack C, Dean L, Gaddy J, Oladele C, Feder S, Canavan M, Nunez-Smith M, Soulos P, Gross C. Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care. Cancer Medicine 2025, 14: e70757. PMID: 40052387, DOI: 10.1002/cam4.70757.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanCarcinoma, Non-Small-Cell LungFemaleHealthcare DisparitiesHumansLung NeoplasmsMaleMedicareRacismSEER ProgramUnited StatesWhiteWhite PeopleConceptsNon-small cell lung cancer carePhase of careSocioeconomic statusNon-small cell lung cancerIndividual-level socioeconomic statusNeighborhood-level socioeconomic statusMedicare-Medicaid dual eligibilityWhite patientsHealth care accessLung cancer careNon-Hispanic blacksIndirect effects of mediatorsDiagnosis stageStage-appropriate treatmentTwo-year survivalCancer careCare accessEffects of raceOptimal careDual eligiblesCareStructural racismRacial inequalityBlack patientsInadequate evaluation
2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchMeSH KeywordsAutoimmune DiseasesCarcinoma, Non-Small-Cell LungFemaleHumansImmunotherapyKidney NeoplasmsLung NeoplasmsMaleRetrospective StudiesConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2023
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply
Voruganti T, Presley C, Gross C. Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply. JAMA Oncology 2023, 9: 1154-1155. PMID: 37347467, DOI: 10.1001/jamaoncol.2023.1538.Peer-Reviewed Original ResearchAssociation Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Non-Small-Cell LungCohort StudiesHumansImmunotherapyLung NeoplasmsMaleRetrospective StudiesConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gain
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply